AI-ready data by design: Standardized, quality-controlled and reproducible quantitative proteomics data, built for integration into large-scale and AI-driven discovery.
Industrial economics, flexible deployment: Unprecedented cost efficiency available as fully outsourced CRO services and in-house proteomics.
Depth meets industrial scale: More than 10,000 proteins from 50,000 cells, scaling from tens to thousands of samples with turnaround times of <3 weeks for 100 samples and <10 weeks for 1,000.
One complete end-to-end solution: An integrated and standardized workflow from sample preparation through high-throughput MS to automated analysis and decision-ready data.
NEWTON, Massachusetts, USA, November 10, 2026 – Life Science Newswire – Biognosys Group, a fully owned affiliate of Bruker Corporation, today announced the launch of Industrialized Discovery.
Modern drug discovery is becoming increasingly data-intensive. Proteomics provides a direct, quantitative view of the molecular layer closest to phenotype. However, proteomics remains difficult to deploy routinely at scale. Moving from individual studies to hundreds or thousands of samples introduces major challenges in cost, throughput, turnaround time and reproducibility.
To address this limitation the Biognosys Group is launching its Industrialized Discovery service which turns proteomics into a standardized, scalable solution for routine use.
It combines universally applicable iST and iST-S sample preparation technologies from PreOmics, state-of-the-art timsTOF mass spectrometers from Bruker, and Spectronaut automated with OmicsFlow data analysis software from Biognosys into a streamlined end-to-end workflow. Quality control is embedded at every stage of the process, enabling highly reproducible and scalable protein quantification across batches, operators, instruments, and study sites.
Industrialized Discovery combines depth, scale and speed without compromising performance. It delivers more than 10,000 protein identifications from as few as 50,000 HEK-293 cells, scales from tens to thousands of samples with throughputs of tens to hundreds per day, and delivers 100 samples in <3 weeks or 1,000 samples in <10 weeks, at unprecedented cost efficiency.
Industrialized Discovery expands both the scale and scope of proteomics experiments, enabling applications that were previously difficult to execute systematically:
Large-scale compound and perturbation screening
Mechanism-of-action (MoA) profiling
Targeted protein degrader (TPD) screening
Large-scale target identification
Population-scale and longitudinal proteomics
Creation of tissue atlases and digital proteomes
Systematic generation of large-scale proteomics datasets for AI-driven biological modelling
"Industrialized Discovery is an important step forward in making proteomics accessible at the scale and quality required for modern drug discovery and translational research," said Oliver Rinner, Senior Vice President of the Biognosys Group. “Proteomics is ideally positioned to provide the deep functional information that the emerging AI based approaches will be able to utilize. The Boston/Cambridge biotech hub with its high density of world leading biotech companies is for us the perfect place to launch this new offer.”
Early User Successes Highlight Real-World Impact
The launch of Industrialized Discovery in Biognosys Group's U.S. laboratories is accompanied by early customer successes that demonstrate the platform's impact in real-world research programs.
Researchers at Novalix combined a DNA-encoded library screening, medicinal chemistry, and advanced biophysical characterization to discover and develop novel PROTAC degraders. Proteome profiling through Industrialized Discovery by Biognosys further strengthened their characterization, providing deeper insights into cellular activity and selectivity.
At Champions Oncology, Industrialized Discovery-type workflows have enabled researchers to generate decision-ready insights from biobank-scale proteomics studies of biological model systems.
Industrialized Discovery is now available through Biognosys Group's U.S. operations and is expected to expand access to large-scale proteomics studies across pharmaceutical, biotechnology, and translational research organizations worldwide.
About Biognosys Group
The Biognosys Group brings together the Bruker Corporation (Nasdaq: BRKR) affiliates Biognosys, biocrates, and PreOmics to deliver integrated solutions across proteomics, metabolomics, and lipidomics. The Group enables seamlessly connected mass spectrometry workflows, making deep omics data accessible to laboratories worldwide.
Its ecosystem spans high-quality consumables, software, and contract research services. Committed to a vendor-agnostic approach, the Biognosys Group supports open collaboration and broad compatibility across leading mass spectrometry platforms. All solutions are modular by design, allowing customers to choose the level of support that best fits their needs, from ready-to-use kits and software to guided implementation, or fully integrated end-to-end CRO services.
For more information, visit www.biognosysgroup.com.
Media Contact
Yasemin Ruest
Teamlead Marketing, Biognosys Group
E: Yasemin.Ruest@biognosys.com